Trials / Withdrawn
WithdrawnNCT02058667
Reirradiation With Concurrent Paclitaxel for Breast Cancer
A Phase I Study of Twice Weekly Paclitaxel and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Kentucky · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial in addition to a dose finding study for concurrent Paclitaxel, will be to establish a treatment algorithm for chest wall reirradiation. A nominal margin of at least 5cm will be used on the protocol and extending it to 7cm. Considering the standard treatment of breast cancer incorporates a cumulative dose of 60Gy, delivering an additional 50.4 Gy followed by a boost should target a total dose of 120 Gy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Paclitaxel+Initial Radiation+Boost | Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy) |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-12-01
- First posted
- 2014-02-10
- Last updated
- 2016-11-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02058667. Inclusion in this directory is not an endorsement.